Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 21, 2026, 11:35 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Ketamine Clear all
Terminated Phase 2 Interventional Results available

Study of Immunomodulation Using Naltrexone and Ketamine for COVID-19

NCT04365985
View directory record Official record
Conditions
COVID-19, Acute Respiratory Distress Syndrome, Severe Acute Respiratory Syndrome (SARS), Coronavirus Infections
Interventions
Naltrexone, Ketamine, Placebo
Drug · Other
Lead sponsor
Corewell Health East
Other
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Royal Oak, Michigan
Source: ClinicalTrials.gov public record
Updated Jan 25, 2022 · Synced Jul 21, 2026, 11:35 PM EDT
Completed Phase 3 Interventional Results available

A Long-term, Safety and Efficacy Study of Intranasal Esketamine in Treatment-resistant Depression

NCT02497287
View directory record Official record
Conditions
Treatment-resistant Depression
Interventions
Esketamine (Intranasal Spray), Duloxetine (Oral Antidepressant), Escitalopram (Oral Antidepressant), Sertraline (Oral Antidepressant), Venlafaxine Extended Release (XR) (Oral Antidepressant)
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
802 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
16
States / cities
New Haven, Connecticut • Miami, Florida • Marietta, Georgia + 13 more
Source: ClinicalTrials.gov public record
Updated Apr 28, 2025 · Synced Jul 21, 2026, 11:35 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Effects of TAK-063 on Preventing Ketamine-Induced Brain Activity Changes as Well as Psychotic-Like Symptoms in Healthy Male Adults

NCT01892189
View directory record Official record
Conditions
Ketamine-Induced Brain Activity Changes, Psychotic-like Symptoms
Interventions
Ketamine, TAK-063, TAK-063 Placebo
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 45 Years · Male only
Enrollment
27 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated May 7, 2026 · Synced Jul 21, 2026, 11:35 PM EDT
Completed Phase 1 Interventional

Dexmedetomidine and Ketamine in MRI

NCT02652507
View directory record Official record
Conditions
Magnetic Resonance Imaging
Interventions
Dexmedetomidine, Ketamine
Drug
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
1 Year to 18 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 23, 2019 · Synced Jul 21, 2026, 11:35 PM EDT
Enrolling by invitation Phase 1 Interventional Accepts healthy volunteers

Induction of Dreaming With EEG and Anesthesia in Healthy Adults

NCT07198711
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Propofol - Emergence-from-LOR Protocol, Propofol - Light Sedation Protocol
Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 70 Years
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Jun 21, 2026 · Synced Jul 21, 2026, 11:35 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Ketamine in the Treatment of Depression

NCT01558063
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Ketamine, Saline, Magnetic Resonance Imaging (MRI)
Drug · Procedure
Lead sponsor
Columbia University
Other
Eligibility
18 Years to 65 Years
Enrollment
38 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2019
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 9, 2019 · Synced Jul 21, 2026, 11:35 PM EDT
Withdrawn Phase 2 Interventional

Effect of Lithium Versus Placebo in Adults With Treatment-Resistant Depression Who Are Receiving Ketamine

NCT03290963
View directory record Official record
Conditions
Treatment Resistant Depression
Interventions
Lithium, Placebo, Ketamine
Drug
Lead sponsor
William V. Bobo, M.D.
Other
Eligibility
18 Years to 64 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Aug 15, 2018 · Synced Jul 21, 2026, 11:35 PM EDT
Completed Phase 2 Interventional Results available

Double-Blind, Placebo-Controlled Trial of Ketamine Therapy in Treatment-Resistant Depression (TRD)

NCT01920555
View directory record Official record
Conditions
Treatment Resistant Depression
Interventions
Ketamine, Placebo Midazolam
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 70 Years
Enrollment
99 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
6
States / cities
Palo Alto, California • New Haven, Connecticut • Boston, Massachusetts + 3 more
Source: ClinicalTrials.gov public record
Updated Jun 18, 2018 · Synced Jul 21, 2026, 11:35 PM EDT
Active, not recruiting Phase 2 Interventional

Single-dose Ketamine Treatment to Improve Depression in Mild Cognitive Impairment

NCT06069843
View directory record Official record
Conditions
Depression, Mild Cognitive Impairment
Interventions
IV Ketamine
Drug
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
50 Years to 90 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 28, 2025 · Synced Jul 21, 2026, 11:35 PM EDT
Completed Phase 4 Interventional Results available

Efficacy Study of Ketamine for Postoperative Pain in Opioid Dependent Patients

NCT01591382
View directory record Official record
Conditions
Postoperative Pain
Interventions
Ketamine, Placebo, Hydromorphone PCA
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 21, 2017 · Synced Jul 21, 2026, 11:35 PM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Examining The Effect Of Ketamine On Glutamate/Glutamine Cycling

NCT02037035
View directory record Official record
Conditions
Depression
Interventions
Ketamine
Drug
Lead sponsor
Yale University
Other
Eligibility
21 Years to 65 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2021
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Sep 7, 2021 · Synced Jul 21, 2026, 11:35 PM EDT
Completed Phase 4 Interventional Results available

Comparison of Nebulized Ketamine to Intravenous Sub-Dissociative Dose Ketamine for Pain

NCT04947085
View directory record Official record
Conditions
Pain
Interventions
Ketamine via Intravenous, Ketamine via BAN
Drug
Lead sponsor
Antonios Likourezos
Other
Eligibility
18 Years to 120 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Brooklyn, New York
Source: ClinicalTrials.gov public record
Updated Jul 2, 2024 · Synced Jul 21, 2026, 11:35 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Long-term Observation of Participants With Mood Disorders

NCT04877977
View directory record Official record
Conditions
Depression, Suicide Risk
Interventions
Not listed
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
18 Years to 99 Years
Enrollment
1,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2028
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 27, 2025 · Synced Jul 21, 2026, 11:35 PM EDT
Terminated Phase 4 Interventional Results available

Ketamine-assisted Therapy for Advanced GI Cancer

NCT06077487
View directory record Official record
Conditions
Pancreatic Ductal Adenocarcinoma, Pain, Acute, Gastrointestinal Cancers, Demoralization
Interventions
Ketamine, Ketamine Injectable Product, Meaning and Purpose therapy, Placebo, Questionnaires
Drug · Behavioral · Other
Lead sponsor
Brian Anderson, MD
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated May 20, 2025 · Synced Jul 21, 2026, 11:35 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Behavioral and Electrophysiological Effects of Ketamine in Treatment-Resistant Depression

NCT04239963
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Not listed
Lead sponsor
Mclean Hospital
Other
Eligibility
18 Years to 70 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2024
U.S. locations
1
States / cities
Belmont, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 29, 2024 · Synced Jul 21, 2026, 11:35 PM EDT
Terminated Phase 2 Interventional Results available

The UTHealth Ketamine Project

NCT02882711
View directory record Official record
Conditions
Treatment Resistant Depression, Major Depressive Disorder, Bipolar Disorder
Interventions
Ketamine
Drug
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
18 Years to 65 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Nov 23, 2020 · Synced Jul 21, 2026, 11:35 PM EDT
Completed Phase 1 Interventional

Continuation Ketamine in Major Depression

NCT00548964
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Lithium, Ketamine
Drug
Lead sponsor
James Murrough
Other
Eligibility
21 Years to 80 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2013
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 22, 2014 · Synced Jul 21, 2026, 11:35 PM EDT
Completed Not applicable Interventional Results available

Study to Find the Dose of Rapidly Administered Ketamine for Brief Painful Procedures in Children

NCT01669642
View directory record Official record
Conditions
Abscess, Fracture
Interventions
Ketamine
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
2 Years to 17 Years
Enrollment
111 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Apr 24, 2019 · Synced Jul 21, 2026, 11:35 PM EDT
Completed Phase 3 Interventional Results available

The Prevention of Delirium and Complications Associated With Surgical Treatments Multi Center Clinical Trial

NCT01690988
View directory record Official record
Conditions
Delirium
Interventions
Ketamine (0.5 mg/kg), Normal Saline (placebo), Ketamine (1 mg/kg)
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
60 Years and older
Enrollment
746 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jun 5, 2018 · Synced Jul 21, 2026, 11:35 PM EDT
Completed Phase 2 Interventional Results available

A Randomized, Placebo-Controlled, Double-Blind Study to Assess Safety and Efficacy of PCN-101 in TRD

NCT05414422
View directory record Official record
Conditions
Treatment Resistant Depression
Interventions
PCN-101, Placebo
Drug
Lead sponsor
Perception Neuroscience
Industry
Eligibility
18 Years to 65 Years
Enrollment
102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022
U.S. locations
13
States / cities
Little Rock, Arkansas • Garden Grove, California • La Jolla, California + 10 more
Source: ClinicalTrials.gov public record
Updated Jun 3, 2024 · Synced Jul 21, 2026, 11:35 PM EDT
Terminated Phase 2 Interventional

Ketamine for OUD and Suicidal Ideation in the ED

NCT06111339
View directory record Official record
Conditions
Opioid Use Disorder, Suicidal Ideation
Interventions
Ketamine, Saline Solution
Drug · Other
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 7, 2025 · Synced Jul 21, 2026, 11:35 PM EDT
Withdrawn Phase 3 Interventional

A Study to Decrease Suicidal Thinking Using Ketamine

NCT02418702
View directory record Official record
Conditions
Depression, Suicide
Interventions
0.2 mg/kg ketamine, placebo
Drug · Other
Lead sponsor
United States Naval Medical Center, San Diego
Federal
Eligibility
18 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Sep 2, 2019 · Synced Jul 21, 2026, 11:35 PM EDT
Terminated Phase 1 Interventional Results available

The Using Postoperative Ketamine and Exploring the Effect on Endometriosis Pain (UPKEEEP) Study

NCT05229653
View directory record Official record
Conditions
Endometriosis, Post Operative Pain
Interventions
Ketamine, Placebo
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 65 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 27, 2025 · Synced Jul 21, 2026, 11:35 PM EDT